Search

Displaying results 2661 - 2670 of 8696 in total
  1. Drug

    Lifitegrast

    go.drugbank.com/drugs/DB11611
    ApprovedInvestigational

    Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    received an ALK-inhibitor on December 18, 2024. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).

    Categories: P-glycoprotein substrates
  3. Drug

    Antithrombin Alfa

    go.drugbank.com/drugs/DB11166
    Approved

    Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations

  4. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene

    Categories: Estrogen Receptor Modulators, P-glycoprotein substrates
  5. Drug

    Levodopa

    go.drugbank.com/drugs/DB01235
    ApprovedInvestigational

    The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after

    Mixtures: Zuades 5 mg/1,25 mg Tabletten zur Herstellung einer Suspension zum Einnehmen für ein Dosiergerät, LEVODOPA P BENS AL 100/25
  6. Drug

    Malathion

    go.drugbank.com/drugs/DB00772
    Approved

    Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice. … Malathion is an irreversible cholinesterase inhibitor and has low human toxicity.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Ferric sulfate

    go.drugbank.com/drugs/DB11171
    Approved

    It is produced by the reaction of sulfuric acid and an oxidizing agent.

  8. Drug

    Ritonavir

    go.drugbank.com/drugs/DB00503
    ApprovedInvestigational

    The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. … While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Benzyl alcohol

    go.drugbank.com/drugs/DB06770
    ApprovedInvestigational

    Mixtures: Skinsept pur - Lösung zur Anwendung auf der Haut, Skinsept color - Lösung zur Anwendung auf der HautCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inhibitors